The global postoperative pain market is expected to be valued at US$ 38.43 Bn in 2023, surpassing US$ 63.8 Bn by 2033. The market is likely projected to rise at a CAGR of 5.2% during the forecast period.
One of the key elements anticipated to support market expansion over the forecast period is the rising prevalence of chronic disorders. The demand for muscle and nerve stimulators has increased as lifestyle problems like obesity and diabetes is becoming more common. Another significant aspect that is predicted to contribute to the market’s growth is the rising incidence of trauma or hypertension. The chance of developing a brain aneurysm and other chronic disorders is markedly increased by hypertension.
Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16040
Due to an increase in surgical operations and the severity of postoperative pain, the global market for postoperative pain therapies is anticipated to expand over the forecast period. As a result of the creation of various novel drugs, it is projected that the market for postoperative pain management would expand globally. New drugs are being developed with large safety margins and beneficial properties.
For the treatment of postoperative pain, non-opioid adjuncts and alternatives are now more crucial than ever. Intravenous (IV) acetaminophen, NSAIDs, magnesium, ketamine, dexmedetomidine, and liposomal bupivacaine are some examples of drugs that have been well-liked in the postoperative pain market. Postoperative pain care is now the norm in both developing and established economies thanks to new medications, increasing demand, easier access, and greater pain control.
Key Takeaways from the Postoperative Pain Market:
- By 2022, the United States is predicted to hold 87.9% of the market for postoperative pain in North America. It is anticipated that the adoption of opioid treatment will slow the opioid epidemic’s spread across North America, especially in the United States.
- Germany is projected to account for 26.9% of the postoperative pain market in Europe in 2022.
- The postoperative pain market in South Korea is projected to expand at a 6.3% CAGR during the forecast period due to the nation’s rising surgical rate.
- Opioids are typically provided for postoperative pain in Japan, however, due to an increase in opioid use for non-medical purposes, regulating authorities are encouraging doctors to prescribe non-opioid drugs, which presents a chance for firms to introduce unique non-opioid drugs.
- The opioid drug class is expected to increase at a 4% CAGR throughout the projection period, accounting for a sizeable share of 61.3% in 2022.
- In terms of route of administration, oral postoperative pain is predicted to hold 37.8% of the market in 2022.
Ask An Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16040
What is the Competition Scenario of the Postoperative Pain Market?
The main strategy used by major suppliers of postoperative pain medications for the development of new product lines of pain medications is the collaboration and acquisition of other pharmaceutical companies. As important stakeholders place more attention on the development of abuse-deterrent opioid medications and the introduction of extended-release non-opioid therapies for post-surgery pain, the demand for painkiller pharmaceuticals is rising. Similar to this, increased efforts to identify and commercialize non-narcotic drugs as well as raising public awareness of postoperative pain management are promoting market expansion.
Latest Developments in the Postoperative Pain Market:
- Assertio Therapeutics, Inc. was acquired by Zyla Life Sciences in May 2020. As a result, a growing commercial pharmaceutical company was able to increase the number of drugs it offered for treating pain, inflammation, and neurology.
- According to Heron Therapeutics, Inc., Health Canada announced in March 2022 the commercialization of ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia following bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty surgical procedures.
- In March 2022, a Phase IIb trial on the perioperative long-acting analgesic drug CPL-01 was completed, and Cali Biosciences Co., Ltd., a biopharmaceutical company specializing in the discovery and development of innovative pharmaceuticals, reported favorable findings.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16040
Postoperative Pain Industry Survey by Category
By Drug Class:
- Opioids
- NSAIDs
- Local Anesthetic
- Acetaminophen
By Route of Administration:
- Injectable
- Oral
- Topical
- Transdermal
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Clinics
- Others
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs